In postmenopausal women with low bone mass, estimated vertebral strength (finite element analysis of CT scans) increased by 18.5% with teriparatide versus 27.3% with romosozumab at month 12.
In plain wordsIn postmenopausal women with low bone mass, estimated spine strength rose less with teriparatide than with romosozumab after 12 months.
- Peptide
- Teriparatide (PTH 1-34)
- Outcome
- DecreaseVertebral strength
- Study
n: not reported in source
- Comparator
- Romosozumab
- Outcome group
- Bone and joint · Musculoskeletal
- Studied dose
- 20 μg daily · 12 monthsAs given in this study (human).
Measurements
- Vertebral strength change
- 18.5%
- teriparatide
- Vertebral strength change
- 27.3%
- romosozumab
Source sentences
We found that, at month 12, vertebral strength increased more for romosozumab compared with both teriparatide (27.3% versus 18.5%; p = 0.005) and placebo (27.3% versus -3.9%; p < 0.0001);
2 context sentences(design, population, supporting numbers)
In a substudy of that trial, which included placebo and teriparatide arms, here we investigated whether those observed increases in BMD also resulted in improvements in estimated strength, as assessed by finite element analysis.
Participants received blinded romosozumab s.c. (210 mg monthly) or placebo, or open-label teriparatide (20 μg daily) for 12 months.